Erste Group Bank Issues Optimistic Forecast for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Investment analysts at Erste Group Bank boosted their FY2026 earnings per share estimates for shares of Bristol Myers Squibb in a research note issued on Friday, June 5th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings of $6.32 per share for the year, up from their previous forecast of $6.31. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.32 per share. Erste Group Bank also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.12 EPS.

Several other equities analysts also recently commented on the stock. HSBC increased their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Guggenheim reissued a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Bank of America cut their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Wall Street Zen lowered Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th. Finally, Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Stock Down 1.5%

Bristol Myers Squibb stock opened at $55.62 on Thursday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The firm’s fifty day simple moving average is $57.90 and its 200-day simple moving average is $56.79. The company has a market capitalization of $113.58 billion, a P/E ratio of 15.62, a P/E/G ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Institutional Trading of Bristol Myers Squibb

Several institutional investors have recently made changes to their positions in the business. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Physician Wealth Advisors Inc. boosted its stake in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares in the last quarter. Bayban bought a new stake in Bristol Myers Squibb in the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb in the fourth quarter valued at $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.